Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 10:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sesame Oil Clear all
Terminated Phase 2 Interventional Results available

Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment

NCT04421456
View directory record Official record
Conditions
Schizophrenia
Interventions
GWP42003-P, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Garden Grove, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 20, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Results available

Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy

NCT04620369
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Nasal Vestibulitis
Interventions
Placebo Administration, Questionnaire Administration, Rose Geranium in Sesame Oil Nasal Spray
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
20
States / cities
Albert Lea, Minnesota • Brainerd, Minnesota • Deer River, Minnesota + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 20, 2026, 10:38 PM EDT
Completed Phase 4 Interventional

Vaginal Compared to Intramuscular Progesterone for Frozen Embryo Transfer

NCT02254577
View directory record Official record
Conditions
Infertility
Interventions
Endometrin® plus Progesterone in Oil (PIO), Progesterone in Oil (PIO) Only
Drug
Lead sponsor
Shady Grove Fertility Reproductive Science Center
Other
Eligibility
18 Years to 48 Years · Female only
Enrollment
1,139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
14
States / cities
Washington D.C., District of Columbia • Annapolis, Maryland • Baltimore, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Sep 20, 2026, 10:38 PM EDT
Withdrawn Phase 4 Interventional

Cannabidiol for Treatment Resistant Depression

NCT04732169
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Active study drug ( oral CBD), matching placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Sep 20, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Results available

Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

NCT02091375
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome
Interventions
GWP42003-P 20 mg/kg/day Dose, Placebo control
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
13
States / cities
Miami, Florida • Orlando, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 20, 2026, 10:38 PM EDT
Terminated Phase 3 Interventional Results available

A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

NCT04252586
View directory record Official record
Conditions
Rett Syndrome, RTT
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
14
States / cities
Birmingham, Alabama • La Jolla, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2022 · Synced Sep 20, 2026, 10:38 PM EDT
Terminated Phase 2 Interventional Results available

Fluphenazine Decanoate for Psoriasis

NCT00356200
View directory record Official record
Conditions
Psoriasis
Interventions
Fluphenazine Decanoate, Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 21, 2010 · Synced Sep 20, 2026, 10:38 PM EDT
Completed Phase 2 Interventional Results available

RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

NCT02090114
View directory record Official record
Conditions
Prostate Cancer
Interventions
Testosterone cypionate, Testosterone Enanthate, Abiraterone acetate, Enzalutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2022 · Synced Sep 20, 2026, 10:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vitamin D's Effect on Physical Performance in the Elderly

NCT02066441
View directory record Official record
Conditions
Family Member
Interventions
Bio-D-Mulsion Forte®, Placebo
Dietary Supplement · Other
Lead sponsor
University of Miami
Other
Eligibility
55 Years and older
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Sep 20, 2026, 10:38 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Oral Androgens in Man-4: (Short Title: Oral T-4)

NCT00399165
View directory record Official record
Conditions
Contraception
Interventions
Testosterone Enanthate, Dutasteride, placebo sesame oil
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2008 · Synced Sep 20, 2026, 10:38 PM EDT
Active, not recruiting Not applicable Interventional

A Clinical Study to Assess the Efficacy of Cannabigerol in Patients with Active Rheumatoid Arthritis.

NCT06513507
View directory record Official record
Conditions
Rheumatoid Arthritis, Inflammatory Disease
Interventions
Cannabigerol (CBG)
Dietary Supplement
Lead sponsor
Raphael Pharma
Industry
Eligibility
25 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 20, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Results available

Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)

NCT02953548
View directory record Official record
Conditions
Infantile Spasms
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month to 24 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Little Rock, Arkansas • Winston-Salem, North Carolina • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 20, 2026, 10:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Peanut Consumption on Postprandial Inflammation, Glucose and Triglycerides

NCT01173042
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Peanuts, Glucose and whipping cream, Oil Blend
Dietary Supplement
Lead sponsor
Penn State University
Other
Eligibility
30 Years to 50 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 20, 2026, 10:38 PM EDT
Completed Phase 2 Interventional Results available

Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance

NCT02286921
View directory record Official record
Conditions
Castration Resistant Metastatic Prostate Cancer
Interventions
Testosterone cypionate, Enzalutamide, Testosterone Enanthate
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
17
States / cities
Birmingham, Alabama • Duarte, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 20, 2026, 10:38 PM EDT
Completed Phase 2 Interventional Results available

A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)

NCT02091206
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome
Interventions
GWP42003-P 5 mg/kg/day Dose, Placebo control, GWP42003-P 10 mg/kg/day Dose, GWP42003-P 20 mg/kg/day Dose
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
4 Years to 10 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 20, 2026, 10:38 PM EDT
Completed Phase 1 Interventional

Efficacy of Epidiolex in Patients With Electrical Status Epilepticus of Sleep (ESES).

NCT04721691
View directory record Official record
Conditions
Electrical Status Epilepticus of Slow-Wave Sleep
Interventions
Epidiolex 100 mg/mL Oral Solution, Placebo
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
2 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 20, 2026, 10:38 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Cannabidiol in Sanfilippo Syndrome

NCT06333041
View directory record Official record
Conditions
Sanfilippo Syndrome, Mucopolysaccharidosis III
Interventions
Epidiolex, Placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
4 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 20, 2026, 10:38 PM EDT
Terminated Phase 2 Interventional

Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults With Autism Spectrum Disorder

NCT03849456
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
GWP42006
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
4 Years to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
3
States / cities
Louisville, Kentucky • Lexington, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 20, 2026, 10:38 PM EDT
Completed Phase 4 Interventional

A Study to Evaluate the Efficacy of the Nasal Antiseptic, PrevinC, When Administered for the RiskReduction of Rhinitis in Subjects Who Work for Child Day Care Centers

NCT02225912
View directory record Official record
Conditions
Upper Respiratory Infections
Interventions
PrevinC, placebo
Other · Drug
Lead sponsor
BioHealth Technologies Inc.
Industry
Eligibility
18 Years to 65 Years
Timeline
2005
U.S. locations
6
States / cities
Hialeah, Florida • Miami, Florida • Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 20, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Results available

A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

NCT02544763
View directory record Official record
Conditions
Tuberous Sclerosis Complex, Seizures
Interventions
GWP42003-P, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 65 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 20, 2026, 10:38 PM EDT
Completed Phase 1 Interventional Results available

University of Alabama at Birmingham (UAB) Adult CBD Program

NCT02700412
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Epidiolex
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Sep 20, 2026, 10:38 PM EDT